Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).

@article{James2015SurvivalWN,
  title={Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).},
  author={Nicholas D James and Melissa R. Spears and Noel W. Clarke and David Paul Dearnaley and Johann S de Bono and Joanna Gale and John Hetherington and Peter J. Hoskin and Robert John Jones and Robert W Laing and Jason Francis Lester and Duncan Mclaren and Christopher C. Parker and Mahesh K B Parmar and Alastair W.S. Ritchie and John Martin Russell and R{\"a}to Thomas Strebel and George N Thalmann and Malcolm David Mason and Matthew R. Sydes},
  journal={European urology},
  year={2015},
  volume={67 6},
  pages={1028-1038}
}
BACKGROUND Prostate cancer (PCa) is the second most common disease among men worldwide. It is important to know survival outcomes and prognostic factors for this disease. Recruitment for the largest therapeutic randomised controlled trial in PCa--the Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy: A Multi-Stage Multi-Arm Randomised Controlled Trial (STAMPEDE)--includes men with newly diagnosed metastatic PCa who are commencing long-term androgen… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 91 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 25 references

CHAARTED: ChemoHormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer [abstract LBA2

  • C Sweeney, Y-H Chen, M Carducci
  • J Clin Oncol
  • 2014
2 Excerpts

Similar Papers

Loading similar papers…